Rostock (ots) - AIDAcara sagt "Tschüß" mit großem Feuerwerk / Zweite Weltreise mit AIDAaura ab 7. Oktober ...
ProMetic Modifies its Organisational Structure
Montreal (ots/PRNewswire) - ProMetic Life Sciences (PLI:TSX) announced today the administrative reorganisation of its communications and business development structure.
By implementing these changes, the Company is focusing its business development activities in key markets providing optimal growth opportunities namely in the United States, Europe, Asia and the Middle East. ProMetic can better achieve this goal through the active involvement of its own business development team already well-established in these markets, and by calling upon its extensive global network.
As part of this reorganisation, Mrs. Sylvie Gosselin, a Communications Manager with some 15 years of experience, and Mrs. Nicole Blanchard, who has been actively practicing investor relations for close to 20 years, have joined the team.
Under this reorganisation, the position of Vice President, Corporate Development, created in 2003 and since held by Mr. Claude Camiré, will be abolished. Mr. Camiré had expressed his intention of joining his family in Toronto. We wish to thank him for his contribution to ProMetic's development and his strong dedication to the success of the Company.
About ProMetic Life Sciences
ProMetic Life Sciences Inc. (TSX-PLI) is a biopharmaceutical company specialised in the research, development, manufacture and marketing of a variety of commercial applications from its proprietary platform technologies, which are used in the development of therapeutics, large-scale purification of biologics and the elimination of pathogens/viruses. Headquartered in Montreal (Canada), ProMetic has additional facilities in the UK and the USA. Visit the Company website at: www.prometic.com
@@start.t1@@ This press release contains forward-looking statements that involve risks
and uncertainties, including, but not limited to the Company's ability to
develop, manufacture, and successfully commercialise value-added
pharmaceutical products and to obtain contracts for its products and
services and commercial acceptance of advanced affinity separation
technology. Shareholders are cautioned that these statements are
predictions and these actual events or results may differ materially from
those anticipated in these forward-looking statements.@@end@@
ots Originaltext: ProMetic Life Sciences
Im Internet recherchierbar: http://www.newsaktuell.ch
For further information: ProMetic Life Sciences Inc., Communications:
Sylvie Gosselin, Communications Manager, ProMetic Life Sciences Inc.,
+1-514-341-2115, ext. 2249, email@example.com; Analysts and
investors: Nicole Blanchard, President, Sun International
Communications, +1-450-627-6600, firstname.lastname@example.org;
Media: Dominic Sicotte, President, Echoes Media Relations Inc.,
+1-514-842-9551, +1-866-633-9551, www.echoesmedia.tv,